Table 2 Patient accountability
FPV/r + ABC/3TC | EFV + ABC/3TC | |
|---|---|---|
ITT:Exposed population, n | 51 | 50 |
Completed 96 weeks on study, n (%) | 34 (67%) | 33 (66%) |
Discontinued study, n (%) | 17 (33%) | 17 (34%) |
Adverse event | 3 (6%) | 2 (4%) |
Lack of efficacy | 5 (10%) | 5 (10%) |
Non-compliance with protocol treatment | 3 (6%) | 2 (4%) |
Lost to follow-up | 6 (12%) | 6 (12%) |
Withdrew consent | 0 | 2 (4%) |